Summary
Global Markets Direct’s, ‘Liver Transplantation - Pipeline Review, H1 2016’, provides an overview of the Liver Transplantation pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Liver Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplantation and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Liver Transplantation
- The report reviews pipeline therapeutics for Liver Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Transplantation therapeutics and enlists all their major and minor projects
- The report assesses Liver Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Transplantation
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Transplantation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Astellas Pharma Inc.
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Dompe Farmaceutici S.p.A.
Novartis AG
RedHill Biopharma Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Transplantation Overview 7
Therapeutics Development 8
Pipeline Products for Liver Transplantation - Overview 8
Pipeline Products for Liver Transplantation - Comparative Analysis 9
Liver Transplantation - Therapeutics under Development by Companies 10
Liver Transplantation - Therapeutics under Investigation by Universities/Institutes 11
Liver Transplantation - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Liver Transplantation - Products under Development by Companies 15
Liver Transplantation - Products under Investigation by Universities/Institutes 16
Liver Transplantation - Companies Involved in Therapeutics Development 17
Astellas Pharma Inc. 17
Conatus Pharmaceuticals Inc. 18
Digna Biotech, S.L. 19
Dompe Farmaceutici S.p.A. 20
Novartis AG 21
RedHill Biopharma Ltd. 22
Liver Transplantation - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ABC-294640 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cardiotrophin-1 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cellular Immunotherapy for Liver Transplantation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cellular Immunotherapy for Liver Transplantation - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
emricasan - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
everolimus - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
FX-06 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
reparixin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
tacrolimus ER - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TR-002 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Liver Transplantation - Recent Pipeline Updates 55
Liver Transplantation - Dormant Projects 69
Liver Transplantation - Discontinued Products 70
Liver Transplantation - Product Development Milestones 71
Featured News & Press Releases 71
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 71
May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients 71
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 72
Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules 73
Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf 0.5mg Capsule Batches 73
Jul 01, 2011: Astellas Introduces Advagraf In India 74
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 74
Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant 74
Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe. 75
Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 77
Disclaimer 78
List of Tables
Number of Products under Development for Liver Transplantation, H1 2016 8
Number of Products under Development for Liver Transplantation - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Liver Transplantation - Pipeline by Astellas Pharma Inc., H1 2016 17
Liver Transplantation - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 18
Liver Transplantation - Pipeline by Digna Biotech, S.L., H1 2016 19
Liver Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 20
Liver Transplantation - Pipeline by Novartis AG, H1 2016 21
Liver Transplantation - Pipeline by RedHill Biopharma Ltd., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Liver Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 55
Liver Transplantation - Dormant Projects, H1 2016 69
Liver Transplantation - Discontinued Products, H1 2016 70
List of Figures
Number of Products under Development for Liver Transplantation, H1 2016 8
Number of Products under Development for Liver Transplantation - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Top 10 Targets, H1 2016 24
Number of Products by Stage and Top 10 Targets, H1 2016 24
Number of Products by Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 26
Number of Products by Routes of Administration, H1 2016 28
Number of Products by Stage and Routes of Administration, H1 2016 28
Number of Products by Molecule Types, H1 2016 30
Number of Products by Stage and Molecule Types, H1 2016 30
